Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: David C. Burns who wrote (1167)	3/25/1999 1:38:00 PM
From: Rob Loney	Read Replies (1) \| Respond to of 1580

Can somebody help me understand. 1) The cornerstone of Merck success has been Cardiovascular sales of enalapril, simvastatin, lovastatin. At least in Canada market share looks like this (enalapril 39% in 1997, 35% in 1998, 33% Feb 99); (Simvastatin 31% in 1997 ,25% in 1998, 24% in 1999); (lovastatin 15% in 1997, 2.7% in 1998). In addition to the loss in market share, Merck has done something very unique for them. Reduce the cost of Zocor? All of this, and the stock continues to go up. Yes, they do have other products, but nothing compared to cardiovascular. What part of the story am I missing?